复发缓解型多发性硬化患者转换为每6周一次那他珠单抗给药与继续每4周一次给药的比较(NOVA):一项随机、对照、开放标签、3b期试验
NOVA试验在11国89个中心纳入499例复发缓解型多发性硬化患者,随机转换为那他珠单抗每6周一次(n=251)或继续每4周一次(n=248)。第72周新增或新扩大T2高信号病灶数在主要估计目标下两组差异未达统计学显著(病灶均数比4.24,95%CI 0.86-20.85,p=0.076),在次要估计目标下差异有统计学意义(病灶均数比4.93,95%CI 1.05-23.20,p=0.044);两组安全性相似。
要点
- 第72周新增或新扩大T2高信号病灶数:每6周组0.20 vs 每4周组0.05(主要估计目标,p=0.076)。
- 次要估计目标下病灶均数比4.93(95%CI 1.05-23.20,p=0.044),差异有统计学意义。
- 每6周组出现1例无症状进行性多灶性白质脑病,每4周组无病例;两组安全性相似。
核心结论
- 第72周新增或新扩大T2高信号病灶数在每6周组与每4周组间存在数值差异,次要估计目标下达统计学显著,但因每4周组疾病活动度低于预期,统计差异的解释受限。
- 那他珠单抗每6周一次与每4周一次的安全性特征相似。
- 本试验未以评估进行性多灶性白质脑病风险差异为效能目标,无症状病例的出现强调对所有接受那他珠单抗治疗患者进行监测和风险因素评估的重要性。
研究设计与样本
- 随机、对照、开放标签、3b期试验(NOVA),在美洲、欧洲和西太平洋11个国家的89个多发性硬化中心进行。
- 纳入18-60岁复发缓解型多发性硬化患者,随机化前已接受静脉那他珠单抗300 mg每4周一次治疗且至少12个月无复发,前3个月无漏给药。
- 499例患者按1:1随机分配至转换为每6周一次(n=251)或继续每4周一次(n=248)。
- 主要终点为第72周新增或新扩大T2高信号病灶数,在至少接受一剂分配治疗且至少有一次基线后MRI、复发、神经检查或疗效评估的参与者中评估。
- 研究入组已关闭,开放标签扩展研究正在进行;试验注册号EudraCT 2018-002145-11和ClinicalTrials.gov NCT03689972。
主要发现
- 2018年12月26日至2019年8月30日,605例患者接受资格评估,499例入组并分配至每6周组(n=251)或每4周组(n=248)。
- 主要估计目标下,第72周新增或新扩大T2高信号病灶均数:每6周组0.20(95%CI 0.07-0.63) vs 每4周组0.05(95%CI 0.01-0.22),病灶均数比4.24(95%CI 0.86-20.85),p=0.076。
- 次要估计目标下,病灶均数:每6周组0.31(95%CI 0.12-0.82) vs 每4周组0.06(95%CI 0.01-0.31),病灶均数比4.93(95%CI 1.05-23.20),p=0.044。
- 每6周组2例参与者出现极端新增或新扩大T2高信号病灶数(≥25),贡献了大部分超额病灶。
- 不良事件:每6周组194/250(78%) vs 每4周组190/247(77%);严重不良事件:每6周组17/250(7%) vs 每4周组17/247(7%);无死亡报告。
局限性
- 每4周组疾病活动度低于预期,限制了对统计差异(或缺乏差异)的解释。
- 本试验未以评估进行性多灶性白质脑病风险差异为效能目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment with natalizumab once every 4 weeks is approved for patients with relapsing-remitting multiple sclerosis, but is associated with a risk of progressive multifocal leukoencephalopathy. Switching to extended-interval dosing is associated with lower progressive multifocal leukoencephalopathy risk, but the efficacy of this approach is unclear. We aimed to assess the safety and efficacy of natalizumab once every 6 weeks compared with once every 4 weeks in patients with relapsing-remitting multiple sclerosis. METHODS: We did a randomised, controlled, open-label, phase 3b trial (NOVA) at 89 multiple sclerosis centres across 11 countries in the Americas, Europe, and Western Pacific. Included participants were aged 18-60 years with relapsing-remitting multiple sclerosis and had been treated with intravenous natalizumab 300 mg once every 4 weeks with no relapses for at least 12 months before randomisation, with no missed doses in the previous 3 months. Participants were randomly assigned (1:1), using a randomisation sequence generated by the study funder and contract personnel with interactive response technology, to switch to natalizumab once every 6 weeks or continue with once every 4 weeks. The centralised MRI reader, independent neurology evaluation committee, site examining neurologists, site backup examining neurologists, and site examining technicians were masked to study group assignments. The primary endpoint was the number of new or newly enlarging T2 hyperintense lesions at week 72, assessed in all participants who received at least one dose of assigned treatment and had at least one postbaseline MRI, relapse, or neurological examination or efficacy assessment. Missing primary endpoint data were handled under prespecified primary and secondary estimands: the primary estimand included all data, regardless of whether participants remained on the assigned treatment; the secondary estimand classed all data obtained after treatment discontinuation or study withdrawal as missing. Safety was assessed in all participants who received at least one dose of study treatment. Study enrolment is closed and an open-label extension study is ongoing. This study is registered with EudraCT, 2018-002145-11, and ClinicalTrials.gov, NCT03689972. FINDINGS: Between Dec 26, 2018, and Aug 30, 2019, 605 patients were assessed for eligibility and 499 were enrolled and assigned to receive natalizumab once every 6 weeks (n=251) or once every 4 weeks (n=248). After prespecified adjustments for missing data, mean numbers of new or newly enlarging T2 hyperintense lesions at week 72 were 0·20 (95% CI 0·07-0·63) in the once every 6 weeks group and 0·05 (0·01-0·22) in the once every 4 weeks group (mean lesion ratio 4·24 [95% CI 0·86-20·85]; p=0·076) under the primary estimand, and 0·31 (95% CI 0·12-0·82) and 0·06 (0·01-0·31; mean lesion ratio 4·93 [95% CI 1·05-23·20]; p=0·044) under the secondary estimand. Two participants in the once every 6 weeks group with extreme new or newly enlarging T2 hyperintense lesion numbers (≥25) contributed most of the excess lesions. Adverse events occurred in 194 (78%) of 250 participants in the once every 6 weeks group and 190 (77%) of 247 in the once every 4 weeks group, and serious adverse events occurred in 17 (7%) and 17 (7%), respectively. No deaths were reported. There was one case of asymptomatic progressive multifocal leukoencephalopathy (without clinical signs) in the once every 6 weeks group, and no cases in the once every 4 weeks group; 6 months after diagnosis, the participant was without increased disability and remained classified as asymptomatic. INTERPRETATION: We found a numerical difference in the mean number of new or newly enlarging T2 hyperintense lesions at week 72 between the once every 6 weeks and once every 4 weeks groups, which reached significance under the secondary estimand, but interpretation of statistical differences (or absence thereof) is limited because disease activity in the once every 4 weeks group was lower than expected. The safety profiles of natalizumab once every 6 weeks and once every 4 weeks were similar. Although this trial was not powered to assess differences in risk of progressive multifocal leukoencephalopathy, the occurrence of the (asymptomatic) case underscores the importance of monitoring and risk factor consideration in all patients receiving natalizumab. FUNDING: Biogen.
引用
- Foley JF, Defer G, Ryerson LZ, et al. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol. 2022. PMID: 35483387. doi:10.1016/S1474-4422(22)00143-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。